Novel therapies for thyroid cancer

Bibliography

• Cramer JD, Fu P, Harth KC, et al. Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results national cancer data registry. Surgery 2010;148(6):1147-52. discussion 1152-3
   PubMed Web of Science ®Google Scholar
• Pellegriti G, Frasca F, Regalbuto C, et al. Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors. J Cancer Epidemiol 2013;2013:965212
   PubMedGoogle Scholar
• Davies L, Welch HG. Increasing incidence of thyroid cancer in the United States, 1973-2002. JAMA 2006;295(18):2164-7
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64(1):9-29
   PubMed Web of Science ®Google Scholar
• Sampson E, Brierley JD, Le LW, et al. Clinical management and outcome of papillary and follicular (differentiated) thyroid cancer presenting with distant metastasis at diagnosis. Cancer 2007;110(7):1451-6
   PubMed Web of Science ®Google Scholar
• Nixon IJ, Whitcher MM, Palmer FL, et al. The impact of distant metastases at presentation on prognosis in patients with differentiated carcinoma of the thyroid gland. Thyroid 2012;22(9):884-9
   PubMed Web of Science ®Google Scholar
• Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994.97(5):418-28. Available from: http://www.ncbi.nlm.nih.gov/pubmed/7977430 [Accessed 9 September 2013]
   Google Scholar
• Durante C, Haddy N, Baudin E, et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 2006;91(8):2892-9
   PubMed Web of Science ®Google Scholar
• Jarząb B, Sporny S, Lange D, et al. [Diagnosis and treatment of thyroid cancer - polish guidelines]. Endokrynol Pol 61(5):518-68. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21049469 [Accessed 9 September 2013]
   Google Scholar
• Pacini F, Schlumberger M, Dralle H, et al. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol 2006;154(6):787-803
   PubMed Web of Science ®Google Scholar
• Cooper DS, Doherty GM, Haugen BR, et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009;19(11):1167-214
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Sherman SI. Approach to the patient with advanced differentiated thyroid cancer. Eur J Endocrinol 2012;166(1):5-11
   PubMed Web of Science ®Google Scholar
• Hundahl SA, Fleming ID, Fremgen AM, Menck HR. A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995 [see commetns]. Cancer 1998.83(12):2638-48. Available from: http://www.ncbi.nlm.nih.gov/pubmed/9874472 [Accessed 9 September 2013]
   Google Scholar
• Massicotte M-H, Brassard M, Claude-Desroches M, et al. Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. Eur J Endocrinol 2014;170(4):575-82
   PubMed Web of Science ®Google Scholar
• Roman S, Lin R, Sosa JA. Prognosis of medullary thyroid carcinoma: demographic, clinical, and pathologic predictors of survival in 1252 cases. Cancer 2006;107(9):2134-42
   PubMed Web of Science ®Google Scholar
• Tuttle R, Ball D, Byrd D, Al E. NCCN Clinical practice guidelines in oncologyn(NCCN Guielines); thyroid carcinoma. NCCN Guidel Version 2. Oncologist 2010;15:212-3. Available from: www.The Oncologist.com
   Google Scholar
• Schlumberger M, Bastholt L, Dralle H, et al. . 2012 European thyroid association guidelines for metastatic medullary thyroid cancer. Eur Thyroid J 2012;1(1):5-14
   Google Scholar
• Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management guidelines of the American Thyroid Association. Thyroid 2009;19(6):565-612
   Google Scholar
• Ahmed M, Barbachano Y, Riddell A, et al. Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based population. Eur J Endocrinol 2011;165(2):315-22
   PubMed Web of Science ®Google Scholar
• Gupta-Abramson V, Troxel AB, Nellore A, et al. Phase II trial of sorafenib in advanced thyroid cancer. J Clin Oncol 2008;26(29):4714-19
   PubMed Web of Science ®Google Scholar
• Lam ET, Ringel MD, Kloos RT, et al. Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer. J Clin Oncol 2010;28(14):2323-30
   PubMed Web of Science ®Google Scholar
• Kloos RT, Ringel MD, Knopp M V, et al. Phase II trial of sorafenib in metastatic thyroid cancer. J Clin Oncol 2009;27(10):1675-84
   PubMed Web of Science ®Google Scholar
• Sherman SI, Wirth LJ, Droz J-P, et al. Motesanib diphosphate in progressive differentiated thyroid cancer. N Engl J Med 2008;359(1):31-42
   PubMed Web of Science ®Google Scholar
• Schlumberger MJ, Elisei R, Bastholt L, et al. Phase II study of safety and efficacy of motesanib in patients with progressive or symptomatic, advanced or metastatic medullary thyroid cancer. J Clin Oncol 2009;27(23):3794-801
   PubMed Web of Science ®Google Scholar
• Cohen EEW, Rosen LS, Vokes EE, et al. Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study. J Clin Oncol 2008;26(29):4708-13
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a phase 2 consortium study. Lancet Oncol 2010;11(10):962-72
   PubMed Web of Science ®Google Scholar
• Bible KC, Suman VJ, Molina JR, et al. A multicenter phase 2 trial of pazopanib in metastatic and progressive medullary thyroid carcinoma: MC057H. J Clin Endocrinol Metab 2014;99(5):1687-93
   PubMed Web of Science ®Google Scholar
• Ravaud A, de la Fouchardière C, Asselineau J, et al. Efficacy of sunitinib in advanced medullary thyroid carcinoma: intermediate results of phase II THYSU. Oncologist 2010;15(2):212-13. author reply 214
   Google Scholar
• Carr LL, Mankoff DA, Goulart BH, et al. Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation. Clin Cancer Res 2010;16(21):5260-8
   PubMed Web of Science ®Google Scholar
• Leboulleux S, Bastholt L, Krause T, et al. Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. Lancet Oncol 2012;13(9):897-905
   PubMed Web of Science ®Google Scholar
• Wells SA, Robinson BG, Gagel RF, et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial. J Clin Oncol 2012;30(2):134-41
   PubMed Web of Science ®Google Scholar
• Elisei R, Schlumberger MJ, Müller SP, et al. Cabozantinib in progressive medullary thyroid cancer. J Clin Oncol 2013;31(29):3639-46
   PubMed Web of Science ®Google Scholar
• Brose MS, Nutting CM, Jarzab B, et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 2014;384(9940):319-28
   PubMed Web of Science ®Google Scholar
• Schlumberger M, Tahara M, Wirth L, et al. A phase 3, multicenter, double blind, placebo-controlled trial of lenvatinib (E7080) in patients 131I-refractory differentiated thyroid cancer (SELECT). J Clin Oncol 2014;32(Suppl):LBA6008
   Google Scholar
• Eng C. RET proto-oncogene in the development of human cancer. J Clin Oncol 1999.17(1):380-93. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10458257 [Accessed 17 July 2014]
   Google Scholar
• Mulligan LM. RET revisited: expanding the oncogenic portfolio. Nat Rev Cancer 2014;14(3):173-86
   PubMed Web of Science ®Google Scholar
• Eng C, Mulligan LM, Smith DP, et al. Mutation of the RET protooncogene in sporadic medullary thyroid carcinoma. Genes Chromosomes Cancer 1995;12(3):209-12
   PubMed Web of Science ®Google Scholar
• Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008;93(3):682-7
   PubMed Web of Science ®Google Scholar
• Moura MM, Cavaco BM, Pinto AE, et al. Correlation of RET somatic mutations with clinicopathological features in sporadic medullary thyroid carcinomas. Br J Cancer 2009;100(11):1777-83
   PubMed Web of Science ®Google Scholar
• Dvorakova S, Vaclavikova E, Sykorova V, et al. Somatic mutations in the RET proto-oncogene in sporadic medullary thyroid carcinomas. Mol Cell Endocrinol 2008;284(1-2):21-7
   Google Scholar
• Giunti S, Antonelli A, Amorosi A, Santarpia L. Cellular signaling pathway alterations and potential targeted therapies for medullary thyroid carcinoma. Int J Endocrinol 2013;2013:803171
   PubMed Web of Science ®Google Scholar
• Cohen Y, Xing M, Mambo E, et al. BRAF mutation in papillary thyroid carcinoma. J Natl Cancer Inst 2003.95(8):625-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12697856 [Accessed 13 July 2014]
   Google Scholar
• Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res 2003.63(7):1454-7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12670889 [Accessed 13 July 2014]
   Google Scholar
• Salvatore G, De Falco V, Salerno P, et al. BRAF is a therapeutic target in aggressive thyroid carcinoma. Clin Cancer Res 2006;12(5):1623-9
   PubMed Web of Science ®Google Scholar
• Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer 2005;12(2):245-62
   PubMed Web of Science ®Google Scholar
• Antonelli A, Fallahi P, Ferrari SM, et al. New targeted therapies for thyroid cancer. Curr Genomics 2011;12(8):626-31
   PubMed Web of Science ®Google Scholar
• Ciampi R, Nikiforov YE. RET/PTC rearrangements and BRAF mutations in thyroid tumorigenesis. Endocrinology 2007;148(3):936-41
   PubMed Web of Science ®Google Scholar
• Espinosa A V, Porchia L, Ringel MD. Targeting BRAF in thyroid cancer. Br J Cancer 2007;96(1):16-20
   PubMed Web of Science ®Google Scholar
• Giusti F, Falchetti A, Franceschelli F, et al. Thyroid cancer: current molecular perspectives. J Oncol 2010;2010:351679
   PubMedGoogle Scholar
• Xing M. Molecular pathogenesis and mechanisms of thyroid cancer. Nat Rev Cancer 2013;13(3):184-99
   PubMed Web of Science ®Google Scholar
• Soh EY, Duh QY, Sobhi SA, et al. Vascular endothelial growth factor expression is higher in differentiated thyroid cancer than in normal or benign thyroid. J Clin Endocrinol Metab 1997;82(11):3741-7
   PubMed Web of Science ®Google Scholar
• De la Torre NG, Buley I, Wass JA, Turner HE. Angiogenesis and lymphangiogenesis in thyroid proliferative lesions: relationship to type and tumour behaviour. Endocr Relat Cancer 2006;13(3):931-44
   PubMed Web of Science ®Google Scholar
• Klein M, Vignaud JM, Hennequin V, et al. Increased expression of the vascular endothelial growth factor is a pejorative prognosis marker in papillary thyroid carcinoma. J Clin Endocrinol Metab 2001;86(2):656-8
   PubMed Web of Science ®Google Scholar
• Bunone G, Vigneri P, Mariani L, et al. Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol 1999;155(6):1967-76
   PubMed Web of Science ®Google Scholar
• Sherman SI. Tyrosine kinase inhibitors and the thyroid. Best Pract Res Clin Endocrinol Metab 2009;23(6):713-22
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002.62(24):7284-90. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12499271 [Accessed 9 July 2014]
   Google Scholar
• Wedge SR, Ogilvie DJ, Dukes M, et al. ZD6474 inhibits vascular endothelial growth factor signaling, angiogenesis, and tumor growth following oral administration. Cancer Res 2002.62(16):4645-55. Available from: http://www.ncbi.nlm.nih.gov/pubmed/12183421 [Accessed 9 July 2014]
   Google Scholar
• Wells SA, Gosnell JE, Gagel RF, et al. Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Oncol 2010;28(5):767-72
   PubMed Web of Science ®Google Scholar
• Robinson BG, Paz-Ares L, Krebs A, et al. Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. J Clin Endocrinol Metab 2010;95(6):2664-71
   PubMed Web of Science ®Google Scholar
• Fox E, Widemann BC, Chuk MK, et al. Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma. Clin Cancer Res 2013;19(15):4239-48
   PubMed Web of Science ®Google Scholar
• Yakes FM, Chen J, Tan J, et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth. Mol Cancer Ther 2011;10(12):2298-308
   PubMed Web of Science ®Google Scholar
• Bentzien F, Zuzow M, Heald N, et al. In vitro and in vivo activity of cabozantinib (XL184), an inhibitor of RET, MET, and VEGFR2, in a model of medullary thyroid cancer. Thyroid 2013;23(12):1569-77
   PubMed Web of Science ®Google Scholar
• Zhang Y, Guessous F, Kofman A, et al.-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. IDrugs 2010.13(2):112-21. Available from: http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=3268517&tool=pmcentrez&rendertype=abstract [Accessed 12 July 2014]
   Google Scholar
• Kurzrock R, Sherman SI, Ball DW, et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol 2011;29(19):2660-6
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Carter C, Tang L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 2004;64(19):7099-109
   PubMed Web of Science ®Google Scholar
• Carlomagno F, Anaganti S, Guida T, et al. BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst 2006;98(5):326-34
   PubMed Web of Science ®Google Scholar
• Hoftijzer H, Heemstra KA, Morreau H, et al. Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma. Eur J Endocrinol 2009;161(6):923-31
   PubMed Web of Science ®Google Scholar
• Capdevila J, Iglesias L, Halperin I, et al. Sorafenib in metastatic thyroid cancer. Endocr Relat Cancer 2012;19(2):209-16
   PubMed Web of Science ®Google Scholar
• Krajewska J, Olczyk T, Roskosz J, et al. Treatment with sorafenib in advanced thyroid cancer - a case report. Endokrynol Pol 61.5):492-6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21049464 [Accessed 13 July 2014]
   Google Scholar
• Shen Y, Ruan M, Luo Q, et al. Brain metastasis from follicular thyroid carcinoma: treatment with sorafenib. Thyroid 2012;22(8):856-60
   PubMed Web of Science ®Google Scholar
• Waguespack SG, Sherman SI, Williams MD, et al. The successful use of sorafenib to treat pediatric papillary thyroid carcinoma. Thyroid 2009;19(4):407-12
   PubMed Web of Science ®Google Scholar
• Iyer P, Mayer JL, Ewig JM. Response to sorafenib in a pediatric patient with papillary thyroid carcinoma with diffuse nodular pulmonary disease requiring mechanical ventilation. Thyroid 2014;24(1):169-74
   PubMed Web of Science ®Google Scholar
• Matsui J, Funahashi Y, Uenaka T, et al. Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase. Clin Cancer Res 2008;14(17):5459-65
   PubMed Web of Science ®Google Scholar
• Glen H, Mason S, Patel H, et al. E7080, a multi-targeted tyrosine kinase inhibitor suppresses tumor cell migration and invasion. BMC Cancer 2011;11:309
   PubMed Web of Science ®Google Scholar
• Okamoto K, Kodama K, Takase K, et al. Antitumor activities of the targeted multi-tyrosine kinase inhibitor lenvatinib (E7080) against RET gene fusion-driven tumor models. Cancer Lett 2013;340(1):97-103
   PubMed Web of Science ®Google Scholar
• Dadu R, Devine C, Hernandez M, et al. Role of salvage targeted therapy in differentiated thyroid cancer patients who failed first-line sorafenib. J Clin Endocrinol Metab 2014;99(6):2086-94
   PubMed Web of Science ®Google Scholar
• Zang J, Wu S, Tang L, et al. Incidence and risk of QTc interval prolongation among cancer patients treated with vandetanib: a systematic review and meta-analysis. PLoS One 2012;7(2):e30353
   PubMed Web of Science ®Google Scholar
• Vandetanib: too dangerous in medullary thyroid cancer. Prescrire Int 2012.21(131):233. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23185843 [Accessed 14 July 2014]
   Google Scholar
• Chen L, Shen Y, Luo Q, et al. Response to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinoma. Thyroid 2011;21(2):119-24
   PubMed Web of Science ®Google Scholar
• Shen C-T, Qiu Z-L, Luo Q-Y. Sorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysis. Endocr Relat Cancer 2014;21(2):253-61
   PubMed Web of Science ®Google Scholar
• Senapati J, Devasia AJ, Ganapule A, et al. Sorafenib Induced hand foot skin rash in FLT3 ITD mutated acute myeloid leukemia-a case report and review of literature. Mediterr J Hematol Infect Dis 2014;6(1):e2014016
   PubMedGoogle Scholar
• Sherman S, Jarzab B, Cabanillas M, et al. A phase II trial of the multitargeted kinase inhibitor E7080 in advanced radioiodine (RAI)-refractory differentiated thyroid cancer (DTC). J Clin Oncol 2011;29(Suppl):5503
   Web of Science ®Google Scholar
• Schlumberger M, Jarzab B, Cabanillas M, et al. A phase II trial of multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC). J Clin Oncol 2012;30(Suppl):5591
   Google Scholar
• Kamba T, McDonald DM. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007;96(12):1788-95
   PubMed Web of Science ®Google Scholar
• Krajewska J, Jarzab B. Lenvatinib for the treatment of follicular and papillary thyroid cancer. Expert Opin Orphan Drugs 2014; doi:10.1517/21678707.2014.962514
   Google Scholar
• Zhang Z-F, Wang T, Liu L-H, Guo H-Q. Risks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysis. PLoS One 2014;9(3):e90135
   Web of Science ®Google Scholar
• Qi W-X, Sun Y-J, Tang L-N, et al. Risk of gastrointestinal perforation in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a systematic review and meta-analysis. Crit Rev Oncol Hematol 2014;89(3):394-403
   PubMed Web of Science ®Google Scholar
• Qi W, Shen Z, Tang L, Yao Y. Congestive heart failure risk in cancer patients treated with VEGFR-TKIs: a systematic review and meta-analysis of 36 clinical trials. Br J Clin Pharmacol 2014;78(4):748-62
   PubMed Web of Science ®Google Scholar
• Qi W-X, Min D-L, Shen Z, et al. Risk of venous thromboembolic events associated with VEGFR-TKIs: a systematic review and meta-analysis. Int J Cancer 2013;132(12):2967-74
   PubMed Web of Science ®Google Scholar
• Izzedine H, Massard C, Spano JP, et al. VEGF signalling inhibition-induced proteinuria: mechanisms, significance and management. Eur J Cancer 2010;46(2):439-48
   PubMed Web of Science ®Google Scholar
• Keizer RJ, Gupta A, Mac Gillavry MR, et al. A model of hypertension and proteinuria in cancer patients treated with the anti-angiogenic drug E7080. J Pharmacokinet Pharmacodyn 2010;37(4):347-63
   PubMed Web of Science ®Google Scholar
• Illouz F, Laboureau-Soares S, Dubois S, et al. Tyrosine kinase inhibitors and modifications of thyroid function tests: a review. Eur J Endocrinol 2009;160(3):331-6
   PubMed Web of Science ®Google Scholar
• Scheffel RS, Dora JM, Siqueira DR, et al. Toxic cardiomyopathy leading to fatal acute cardiac failure related to vandetanib: a case report with histopathological analysis. Eur J Endocrinol 2013;168(6):K51-4
   Web of Science ®Google Scholar
• Toubert M-E, Vercellino L, Faugeron I, et al. Fatal heart failure after a 26-month combination of tyrosine kinase inhibitors in a papillary thyroid cancer. Thyroid 2011;21(4):451-4
   PubMed Web of Science ®Google Scholar
• Klein Hesselink EN, Klein Hesselink MS, de Bock GH, et al. Long-term cardiovascular mortality in patients with differentiated thyroid carcinoma: an observational study. J Clin Oncol 2013;31(32):4046-53
   PubMed Web of Science ®Google Scholar
• Feldt S, Schüssel K, Quinzler R, et al. Incidence of thyroid hormone therapy in patients treated with sunitinib or sorafenib: a cohort study. Eur J Cancer 2012;48(7):974-81
   PubMed Web of Science ®Google Scholar
• Makita N, Iiri T. Tyrosine kinase inhibitor-induced thyroid disorders: a review and hypothesis. Thyroid 2013;23(2):151-9
   PubMed Web of Science ®Google Scholar
• Illouz F, Braun D, Briet C, et al. Thyroid effects of tyrosine kinase inhibitors. Eur J Endocrinol 2014;171(3):91-9; doi: 10.1530/EJE-14-0198. [ Epub 2014 May 15]
   PubMed Web of Science ®Google Scholar
• Abdulrahman RM, Verloop H, Hoftijzer H, et al. Sorafenib-induced hypothyroidism is associated with increased type 3 deiodination. J Clin Endocrinol Metab 2010;95(8):3758-62
   PubMed Web of Science ®Google Scholar
• Braun D, Kim TD, le Coutre P, et al. Tyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transport. J Clin Endocrinol Metab 2012;97(1):E100-5
   PubMed Web of Science ®Google Scholar
• Bowen JM. Mechanisms of TKI-induced diarrhea in cancer patients. Curr Opin Support Palliat Care 2013;7(2):162-7
   PubMed Web of Science ®Google Scholar